Overview We are a biopharmaceutical company focused on discovering, developing and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. We have discovered and are developing muscle-directed investigational medicines that may potentially improve the healthspan of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function. Our first commercial p...
Q2 FY2026 — expected 2026-09-11
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001193125-26-076495 | EDGAR | 73K words |
| 2025-02-27 | 2024-12-31 | 0000950170-25-029206 | EDGAR | — |
| 2024-02-28 | 2023-12-31 | 0000950170-24-022256 | EDGAR | — |
| 2023-03-01 | 2022-12-31 | 0000950170-23-005515 | EDGAR | — |
| 2022-02-25 | 2021-12-31 | 0001564590-22-007218 | EDGAR | — |
| 2021-02-26 | 2020-12-31 | 0001564590-21-009467 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-05 | 2025-09-30 | 0001193125-25-267059 | EDGAR | 49K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-105108 | EDGAR | — |
| 2025-05-06 | 2025-03-31 | 0000950170-25-064529 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0000950170-24-123283 | EDGAR | — |
| 2024-08-09 | 2024-06-30 | 0000950170-24-094743 | EDGAR | — |
| 2024-05-10 | 2024-03-31 | 0000950170-24-057805 | EDGAR | — |
| 2023-11-03 | 2023-09-30 | 0000950170-23-058914 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0000950170-23-037995 | EDGAR | — |
| 2023-05-05 | 2023-03-31 | 0000950170-23-018305 | EDGAR | — |
| 2022-11-04 | 2022-09-30 | 0000950170-22-022207 | EDGAR | — |
| 2022-08-05 | 2022-06-30 | 0000950170-22-015117 | EDGAR | — |
| 2022-05-06 | 2022-03-31 | 0000950170-22-008125 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-24 | 0001193125-26-067012 | EDGAR | 4K words |
| 2026-02-17 | 0001193125-26-053049 | EDGAR | — |
| 2025-12-19 | 0001193125-25-326778 | EDGAR | — |
| 2025-12-12 | 0001193125-25-316904 | EDGAR | — |
| 2025-11-14 | 0001193125-25-282889 | EDGAR | — |
| 2025-11-05 | 0001193125-25-266842 | EDGAR | — |
| 2025-09-22 | 0001193125-25-209437 | EDGAR | — |
| 2025-09-16 | 0001193125-25-204991 | EDGAR | — |
| 2025-09-03 | 0000950170-25-112570 | EDGAR | — |
| 2025-09-02 | 0000950170-25-112564 | EDGAR | — |
198 total filings indexed. 170 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001061983 |
| Ticker | CYTK |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Website | https://www.cytokinetics.com |
| Listed | 2004-04-29 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report